Infectran

INFLECTRA is a medication used to treat various inflammatory conditions, including Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. It works by blocking a protein called tumor necrosis factor (TNF), which is involved in inflammation.

For Crohn’s disease and ulcerative colitis, INFLECTRA is administered through an intravenous infusion over at least two hours. The initial dose is 5 mg/kg at weeks 0, 2, and 6, followed by a maintenance dose of 5 mg/kg every eight weeks. Some patients may need a higher dose of 10 mg/kg if they lose their response to treatment.

INFLECTRA is also used in combination with methotrexate for rheumatoid arthritis. It helps reduce symptoms, prevent structural damage, and improve physical function in patients with active rheumatoid arthritis.

In addition to its therapeutic benefits, it’s essential to monitor patients for potential side effects and complications, such as infections, heart failure, and hepatosplenic T-cell lymphoma, a rare but serious condition. Regular follow-up visits with a healthcare provider are crucial to ensure the medication is working effectively and to address any concerns promptly.

Before starting treatment, patients should be tested for latent tuberculosis and treated if necessary. This is because TNF blockers like INFLECTRA can reactivate latent TB. Patients should also be aware of the risk of opportunistic infections, such as histoplasmosis and coccidioidomycosis, and seek medical attention if they experience severe systemic illness.

Overall, INFLECTRA is a powerful medication that can significantly improve the quality of life for patients with severe inflammatory conditions, but it requires careful monitoring and adherence to treatment guidelines to ensure its safe and effective use.